Meeting
2017 ASCO Annual Meeting
Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.
Authors
Kian-Huat Lim
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
Kian-Huat Lim , Albert C. Lockhart , Saiama Naheed Waqar , Ramaswamy Govindan , Daniel Morgensztern , Joel Picus , Benjamin R. Tan Jr., Maria Quintos Baggstrom , Emily Ratchford , Samantha Marquez , Andrea Wang-Gillam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT01677559
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2553)
DOI
10.1200/JCO.2017.35.15_suppl.2553
Abstract #
2553
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors.
First Author: Toshihiko Doi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).
First Author: John Davelaar
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2019 ASCO Annual Meeting
First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.
First Author: Debbie Robbrecht